30 completed, 8 terminated, 4 withdrawn, 3 active not recruiting. 45 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 45 | Completed 30, Terminated 8, Withdrawn 4, Active not recruiting 3 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Carcinoma, Islet Cell: new trials by email Literature Review of Carcinoma, Islet Cell trials Research Report on Carcinoma, Islet Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multicenter Trial of ESK981 in Patients With Select Solid Tumors ESK981 - Pancreatic Adenocarcinoma, Adenosquamous Carcinoma | Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 17 | 2024-04-19 | 2026-05-14 |
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs 177Lu-DOTATOC - Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Withdrawn | British Columbia Cancer Agency | 2023-01-15 | 2023-02-21 | |
| Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin Fluorouracil, Leucovorin, Liposomal Irinotecan - Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 11 | 2019-06-17 | 2025-01-30 |
| Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Sapanisertib - Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2 | Phase 2 | Completed | National Cancer Institute (NCI) | 13 | 2017-04-28 | 2023-10-17 |
| FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF) - Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 2 | 2017-02-01 | 2020-11-27 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors regorafenib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | University of Southern California | 3 | 2016-08-16 | 2021-12-15 |
| Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas Capecitabine, Carboplatin, Cisplatin - Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 67 | 2015-11-06 | 2026-11-02 |
| A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Palbociclib - Pancreatic Neuroendocrine Cancer | Phase 2 | Completed | Grupo Espanol de Tumores Neuroendocrinos | 21 | 2015-05-01 | 2018-01-23 |
| Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate - Pancreatic Neuroendocrine Carcinoma | Phase 2 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 84 | 2015-02-01 | 2025-04-20 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Everolimus - Estrogen Receptor-positive Breast Cancer, Gastrinoma | Phase 2 | Terminated | Emory University | 2 | 2014-11-01 | 2017-02-03 |
| Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors dovitinib lactate, pharmacological study, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2014-10-01 | 2017-07-19 | |
| Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Ziv-Aflibercept - Multiple Endocrine Neoplasia Type 1, Pancreatic Neuroendocrine Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2014-06-18 | 2020-03-23 |
| Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery everolimus, placebo - Gastrinoma, Glucagonoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 2 | 2014-04-10 | 2023-06-29 |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors temozolomide, capecitabine - Gastrinoma, Glucagonoma | Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 144 | 2013-08-08 | 2026-09-29 |
| Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT gallium Ga 68-edotreotide, positron emission tomography/computed tomography, indium In 111 pentetreotide - Adult Medulloblastoma, Childhood Medulloblastoma | Phase 2 | Completed | Sue O'Dorisio | 68 | 2013-04-01 | 2021-09-22 |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Capecitabine, Temozolomide, Bevacizumab - Gastrinoma, Glucagonoma | Phase 2 | Completed | Shaheen Shagufta | 20 | 2012-12-01 | 2024-02-06 |
| Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery temozolomide, pazopanib hydrochloride - Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Carcinoma | Phase 1 / Phase 2 | Completed | Northwestern University | 29 | 2011-12-12 | 2021-08-05 |
| Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Bevacizumab, Everolimus, Octreotide Acetate - Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 150 | 2010-10-15 | 2022-08-04 |
| Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Bortezomib, Panobinostat - Pancreatic Cancer | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 7 | 2010-09-01 | 2017-12-28 |
Showing 20 of 45. Sign in to see all of them.
Somatostatinoma (33) · Gastrinoma (22) · Insulinoma (21) · Glucagonoma (20) · Vipoma (13) · Adenoma, Islet Cell (11) · Neuroendocrine Tumors (10) · Neoplasms (8) · Neoplasm Metastasis (6) · Pancreatic Neoplasms (6) · Carcinoid Tumor (5) · Carcinoma, Neuroendocrine (5) · Pheochromocytoma (5) · Zollinger-Ellison Syndrome (4)
Adenocarcinoma (45) · Digestive System Diseases (45) · Digestive System Neoplasms (45) · Endocrine Gland Neoplasms (45) · Endocrine System Diseases (45) · Neoplasms by Histologic Type (45) · Neoplasms by Site (45) · Neoplasms, Glandular and Epithelial (45) · Pancreatic Diseases (45) · Carcinoma (42) · Neoplasms, Germ Cell and Embryonal (40) · Neuroectodermal Tumors (40) · Pancreatic Neoplasms (39) · Neoplasms (37) · Carcinoma, Neuroendocrine (34)
Capecitabine (5) · Everolimus (5) · Octreotide (5) · Temozolomide (5) · Bevacizumab (4) · Fluorouracil (4) · Leucovorin (3) · Biological Therapy (2) · Bortezomib (2) · Cisplatin (2) · Disulfides (2) · Immunoglobulin G (2) · Magnetic Resonance Spectroscopy (2) · Melphalan (2) · Sirolimus (2)
National Cancer Institute (NCI) (10) · ECOG-ACRIN Cancer Research Group (3) · Eastern Cooperative Oncology Group (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Novartis Pharmaceuticals (2) · Academic and Community Cancer Research United (1) · British Columbia Cancer Agency (1) · Burzynski Research Institute (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Columbia University (1) · Delcath Systems Inc. (1) · Eli Lilly and Company (1) · Emory University (1) · Federation Francophone de Cancerologie Digestive (1) · Grupo Espanol de Tumores Neuroendocrinos (1)
United States (37) · Canada (5) · France (2) · Spain (2) · Argentina (1) · Australia (1) · Belgium (1) · Germany (1) · Guam (1) · Italy (1) · Netherlands (1) · Sweden (1) · United Kingdom (1)
Mary Mulcahy, MD (2) · Timothy Hobday (2) · Arkadiusz Dudek, MD (1) · Daniel Halperin (1) · Ebrahim Delpassand, M.D. (1) · Emily Bergsland (1) · Emily K. Bergsland, MD (1) · Francois Benard, MD (1) · Guillaume Cadiot (1) · H. Richard Alexander, MD, FACS (1) · Halla Nimeiri (1) · Henry Pitot (1)
PMID 14673042, PMID 21831734, PMID 25318437, PMID 25488966, PMID 25956795, PMID 29853660, PMID 31969335, PMID 33362722, PMID 33835977, PMID 33882143, PMID 34380663, PMID 34716198, PMID 36260828, PMID 37702588, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 39863139, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42225102, PMID 42499790
N01CM62205 (3), U10CA180820 (3), N01CM00039 (2), P30CA016672 (2), U10CA021115 (2), N01CM00032 (1), N01CM00038 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM17102 (1), N01CM17105 (1), N01CM17107 (1), N01CM62201 (1)